Bristol-Myers Squibb Company
BMYHealthcareNASDAQDrug Manufacturers - General
Scan Results
Daily timeframeBristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. At a $116.77B market cap, Bristol-Myers Squibb Company ranks as a large-cap company within healthcare. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas.
Market Cap
$116.77B
Beta
0.26
P/E (TTM)
16.02
P/E (Fwd)
9.27
EPS (TTM)
$3.57
EPS (Fwd)
$6.17
ROE
38.7%
ROA
10.7%
Cash
$10.49B
Total Debt
$46.43B
Free CF
$9.85B
52W Change
17.2%
Annual Financials
Cash vs Debt
Bristol-Myers Squibb Company carries $46.43B in total debt against $10.49B in cash reserves — debt is roughly 4.4x the cash position. Managing this leverage effectively will be important for long-term financial stability. Annual free cash flow of $9.85B supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 38.7% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Return on assets of 10.7% further supports the picture of efficient asset utilization. Revenue has been relatively flat, moving from $46.16B (2022) to $48.20B (2025).
BMY's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing BMY.